Inovio Pharma Stock
Inovio Pharma Stock
Our community is currently high on Inovio Pharma with 3 Buy predictions and 1 Sell predictions.
With a target price of 3 € there is potential for a 463.91% increase which would mean more than doubling the current price of 0.53 € for Inovio Pharma.
Our community identified positive and negative aspects for Inovio Pharma stock for the coming years. 1 users see the criterium "Business model" as a plus for the Inovio Pharma stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
Pros and Cons of Inovio Pharma in the next few years
Pros
?
S********** s********
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Cons
?
C******** o* t** e**********
?
B****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Inovio Pharma vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Inovio Pharma | - | - | - | - | - | - | - |
| Evolus Inc | -0.650% | -4.599% | -13.132% | -33.084% | -4.844% | -41.730% | -44.237% |
| Heron Therapeutics Inc. | -1.120% | 4.313% | 19.752% | -70.510% | -60.054% | -70.530% | -95.574% |
| Rhythm Pharmaceuticals | -1.630% | -6.383% | -10.660% | 15.033% | -5.882% | 303.670% | 547.059% |
Comments
Inovio Pharmaceuticals (INO) had its "overweight" rating reaffirmed by Piper Sandler. They now have a $4.00 price target on the stock, down from $6.00.
Show more
Ratings data for INO provided by MarketBeat
Inovio Pharmaceuticals (INO) was downgraded by Wall Street Zen from "hold" to "sell".
Show more
Ratings data for INO provided by MarketBeat
Inovio Pharmaceuticals (NASDAQ:INO) had its "overweight" rating reaffirmed by analysts at UBS Group AG.
Show more
Ratings data for INO provided by MarketBeat